Curaleaf Sweetens Hostile Aurora Bid 25% to US$5.00/Share, Extends Deadline to Dec 4
CURLF sits 81% above its 52-week low of $5.4 on elevated volume (3.1× avg).
Summary
Curaleaf increased its hostile bid for Aurora Cannabis by 25% to US$5.00 per share, raised the cap price to US$6.00, and extended the tender deadline to December 4, 2026.
Key Events · M&A and Partnerships · CURLF
-
Offer Increased 25% to US$5.00/Share
Cash consideration raised 33% from US$0.75 to US$1.00 per Aurora share; share consideration raised from 0.3463 to 0.4013 Curaleaf shares, lifting total implied value from US$4.00 to US$5.00 per share.
-
Cap Price Raised 20% to US$6.00
Maximum consideration per Aurora share increased from US$5.00 to US$6.00, representing an 86% premium to Aurora's unaffected 30-day VWAP of US$2.75 as of August 10, 2026.
-
Deadline Extended to December 4, 2026
Expiry Time moved from December 1 to December 4, 2026 at 11:59 p.m. Mountain Time, giving Aurora shareholders additional time to tender.
-
4.16M Additional Curaleaf Shares Registered
F-80 registers 4,162,854 additional subordinate voting shares, bringing total registered to 28,183,875.67 shares to cover the increased share consideration under the amended exchange ratio of 0.3762.
Analysis · CURLF · Life Sciences
Curaleaf raised its hostile takeover offer for Aurora Cannabis by 25%, increasing cash from US$0.75 to US$1.00 per share and share consideration from 0.3463 to 0.4013 Curaleaf shares, lifting total implied value to US$5.00 per Aurora share. The cap price also rose 20% to US$6.00. This is a material escalation of a contested M&A battle — Aurora's board has repeatedly rejected the offer and is fighting Curaleaf's attempt to halt its ATM program. The enhanced terms signal Curaleaf's determination to close the deal despite Aurora's refusal to engage, and the extended December 4 deadline gives Aurora shareholders more time to tender. The filing also registers 4.16 million additional Curaleaf shares to cover the increased stock component, implying up to 28.2 million shares could be issued if the offer succeeds — meaningful dilution for Curaleaf holders but a richer payout for Aurora shareholders.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.9% of the 285 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $9.76 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.